Fruquintinib

Drug Profile

Fruquintinib

Alternative Names: HMPL-013

Latest Information Update: 23 Jun 2017

Price : $50

At a glance

  • Originator Hutchison MediPharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Colorectal cancer
  • Phase III Non-small cell lung cancer
  • Phase II Solid tumours
  • Phase I Gastric cancer

Most Recent Events

  • 12 Jun 2017 Preregistration for Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO)
  • 12 Jun 2017 China Food and Drug Administration (CFDA) accepts NDA for fruquintinib for Colorectal cancer (Late stage disease, Metastatic disease, Second-line therapy or greater) for review
  • 05 Jun 2017 Updated efficacy and adverse events data from a phase III trial in Colorectal cancer presented at the American Society of Clinical Oncology Annual Meeting (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top